Search

Your search keyword '"Leiter, Lawrence A."' showing total 2,438 results
Start Over Author "Leiter, Lawrence A."
2,438 results on '"Leiter, Lawrence A."'

151. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension

Author

Daskalopoulou, Stella S., Rabi, Doreen M., Zarnke, Kelly B., Dasgupta, Kaberi, Nerenberg, Kara, Cloutier, Lyne, Gelfer, Mark, Lamarre-Cliche, Maxime, Milot, Alain, Bolli, Peter, McKay, Donald W., Tremblay, Guy, McLean, Donna, Tobe, Sheldon W., Ruzicka, Marcel, Burns, Kevin D., Vallée, Michel, Ramesh Prasad, G.V., Lebel, Marcel, Feldman, Ross D., Selby, Peter, Pipe, Andrew, Schiffrin, Ernesto L., McFarlane, Philip A., Oh, Paul, Hegele, Robert A., Khara, Milan, Wilson, Thomas W., Brian Penner, S., Burgess, Ellen, Herman, Robert J., Bacon, Simon L., Rabkin, Simon W., Gilbert, Richard E., Campbell, Tavis S., Grover, Steven, Honos, George, Lindsay, Patrice, Hill, Michael D., Coutts, Shelagh B., Gubitz, Gord, Campbell, Norman R.C., Moe, Gordon W., Howlett, Jonathan G., Boulanger, Jean-Martin, Prebtani, Ally, Larochelle, Pierre, Leiter, Lawrence A., Jones, Charlotte, Ogilvie, Richard I., Woo, Vincent, Kaczorowski, Janusz, Trudeau, Luc, Petrella, Robert J., Hiremath, Swapnil, Stone, James A., Drouin, Denis, Lavoie, Kim L., Hamet, Pavel, Fodor, George, Grégoire, Jean C., Fournier, Anne, Lewanczuk, Richard, Dresser, George K., Sharma, Mukul, Reid, Debra, Benoit, Geneviève, Feber, Janusz, Harris, Kevin C., Poirier, Luc, and Padwal, Raj S.

Published
2015
Full Text
View/download PDF

153. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers

Author

Yale, Jean-François, primary, Roborel de Climens, Aude, additional, Aggarwal, Naresh, additional, Dex, Terry, additional, Gerstein, Hertzel C., additional, Harris, Stewart, additional, Hramiak, Irene, additional, Stewart, John, additional, and Leiter, Lawrence A., additional

Published
2022
Full Text
View/download PDF

154. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials

Author

Koenig, Wolfgang, primary, Conde, Lorena Garcia, additional, Landmesser, Ulf, additional, Leiter, Lawrence A., additional, Ray, Kausik K., additional, Schwartz, Gregory G., additional, Wright, R Scott, additional, Han, Jackie, additional, and Raal, Frederick J., additional

Published
2022
Full Text
View/download PDF

155. Glycemic Index Versus Wheat Fiber on Arterial Wall Damage in Diabetes: A Randomized Controlled Trial

Author

Jenkins, David J.A., primary, Chiavaroli, Laura, additional, Mirrahimi, Arash, additional, Mitchell, Sandra, additional, Faulkner, Dorothea, additional, Sahye-Pudaruth, Sandhya, additional, Paquette, Melanie, additional, Coveney, Judy, additional, Olowoyeye, Omodele, additional, Patel, Darshna, additional, Pichika, Sathish Chandra, additional, Bashyam, Balachandran, additional, Maraj, Tishan, additional, Gillett, Chantal, additional, de Souza, Russell J., additional, Augustin, Livia S.A., additional, Blanco Mejia, Sonia, additional, Nishi, Stephanie K., additional, Leiter, Lawrence A., additional, Josse, Robert G., additional, McKeown-Eyssen, Gail E., additional, Berger, Alan R., additional, Connelly, Philip W., additional, Srichaikul, Korbua, additional, Kendall, Cyril W.C., additional, Sievenpiper, John L., additional, and Moody, Alan R., additional

Published
2022
Full Text
View/download PDF

156. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Author

Das Pradhan, Aruna, primary, Glynn, Robert J., additional, Fruchart, Jean-Charles, additional, MacFadyen, Jean G., additional, Zaharris, Elaine S., additional, Everett, Brendan M., additional, Campbell, Stuart E., additional, Oshima, Ryu, additional, Amarenco, Pierre, additional, Blom, Dirk J., additional, Brinton, Eliot A., additional, Eckel, Robert H., additional, Elam, Marshall B., additional, Felicio, João S., additional, Ginsberg, Henry N., additional, Goudev, Assen, additional, Ishibashi, Shun, additional, Joseph, Jacob, additional, Kodama, Tatsuhiko, additional, Koenig, Wolfgang, additional, Leiter, Lawrence A., additional, Lorenzatti, Alberto J., additional, Mankovsky, Boris, additional, Marx, Nikolaus, additional, Nordestgaard, Børge G., additional, Páll, Dénes, additional, Ray, Kausik K., additional, Santos, Raul D., additional, Soran, Handrean, additional, Susekov, Andrey, additional, Tendera, Michal, additional, Yokote, Koutaro, additional, Paynter, Nina P., additional, Buring, Julie E., additional, Libby, Peter, additional, and Ridker, Paul M, additional

Published
2022
Full Text
View/download PDF

157. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Author

Pollack, Rena, primary, Raz, Itamar, additional, Wiviott, Stephen D., additional, Goodrich, Erica L., additional, Murphy, Sabina A., additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Mosenzon, Ofri, additional, Langkilde, Anna Maria, additional, Gause-Nilsson, Ingrid A.M., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P.H., additional, Sabatine, Marc S., additional, and Cahn, Avivit, additional

Published
2022
Full Text
View/download PDF

158. Glycemic Index versus Wheat Fiber on Arterial Wall Damage in Diabetes: a randomized controlled trial

Author

Jenkins, David J A, primary, Chiavaroli, Laura, primary, Mirrahimi, Arash, primary, Mitchell, Sandra, primary, Faulkner, Dorothea, primary, Sahye-Pudaruth, Sandhya, primary, Paquette, Melanie, primary, Coveney, Judy, primary, Olowoyeye, Omodele, primary, Patel, Darshna, primary, Pichika, Sathish Chandra, primary, Bashyam, Balachandran, primary, Maraj, Tishan, primary, Gillett, Chantal, primary, Souza, Russell J. de, primary, Augustin, Livia S, primary, Mejia, Sonia Blanco, primary, Nishi, Stephanie K, primary, Leiter, Lawrence A, primary, Josse, Robert G, primary, McKeown-Eyssen, Gail E, primary, Berger, Alan R, primary, Connelly, Philip W, primary, Srichaikul, Korbua, primary, Kendall, Cyril W C, primary, Sievenpiper, John L, primary, and Moody, Alan R, primary

Published
2022
Full Text
View/download PDF

159. Important Food Sources of Sugars and Type 2 Diabetes: A Systematic Review and Meta-analysis of Prospective Cohort Studies

Author

Khan, Tauseef, primary, Chen, Victoria, additional, Lee, Danielle, additional, Tayyiba, Mobushra, additional, Saleh, Ahmed, additional, Ahmed, Amna, additional, Au-Yeung, Fei, additional, Mejia, Sonia Blanco, additional, Chiavaroli, Laura, additional, Malik, Vasanti, additional, Leiter, Lawrence, additional, Wolever, Thomas, additional, Kendall, Cyril, additional, and Sievenpiper, John, additional

Published
2022
Full Text
View/download PDF

160. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

Author

Zelniker, Thomas, Wiviott, Stephen D, Mosenzon, Ofri, Goodrich, Erica L, Jarolim, Petr, Cahn, Avivit, Bhatt, Deepak, A. Leiter, Lawrence, McGuire, Darren K., Wilding, John, oleg, averkov, Budaj, Andrzej, Parkhomenko, A., Ray, Kausik, Gause-Nilsson, Ingrid, Langkilde, A, Fredriksson, Martin, Raz, Itamar, S. Sabatine, Marc, and Morrow, David A

Subjects
Cardiology (incl. cardiovascular diseases), Cardiology and Cardiovascular Medicine
Abstract

ImportanceDapagliflozin reduces the risk of hospitalizations for heart failure and the progression of chronic kidney disease in patients with and without type 2 diabetes (T2D), whereas the effects on reducing atherosclerotic events appear less clear.ObjectiveTo explore whether N-terminal pro–B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hsTnT) levels can identify a subset of patients with T2D at higher risk and who might benefit more from dapagliflozin with regard to atherosclerotic events.Design, Setting, and ParticipantsThis was a secondary analysis of the DECLARE-TIMI 58 trial, a randomized clinical trial of dapagliflozin in patients with T2D and either multiple risk factors for atherosclerotic cardiovascular disease (ASCVD; approximately 60%) or established ASCVD (approximately 40%). All patients with available blood samples at randomization were included in these analyses. Data were collected from May 2013 to September 2018, and data were analyzed from May 2019 to June 2022.InterventionsDapagliflozin vs placebo.Main Outcomes and MeasuresMajor adverse cardiovascular events (MACE), the composite of myocardial infarction, ischemic stroke, or cardiovascular death, which was one of dual primary outcomes of the main trial.ResultsOf 14 565 included patients, 9143 (62.8%) were male, and the mean (SD) age was 63.9 (6.8) years. When tested individually in a multivariable model for MACE risk, NT-proBNP and hsTnT were each significantly associated with the risk of MACE (adjusted hazard ratio [aHR] per 1 SD in log-transformed biomarker: NT-proBNP, 1.62; 95% CI, 1.49-1.76; hsTnT: 1.59; 95% CI, 1.46-1.74). The magnitude of the association was similar in patients with ASCVD (NT-proBNP: aHR, 1.60; 95% CI, 1.45-1.77; hsTnT: aHR, 1.62; 95% CI, 1.45-1.81) and multiple risk factors for ASCVD (NT-proBNP: aHR, 1.62; 95% CI, 1.40-1.88; hsTnT: aHR, 1.51; 95% CI, 1.29-1.77). Moreover, both biomarkers remained independently associated with MACE when both were included in the multivariable model (NT-proBNP: aHR, 1.46; 95% CI, 1.34-1.60; hsTnT: aHR, 1.39; 95% CI, 1.26-1.53). Modeled as a continuous variable, baseline biomarker levels did not modify the relative treatment effect of dapagliflozin vs placebo with MACE. However, the relative risk reduction numerically grew with higher biomarker levels, as did the baseline risk. Thus, MACE event rates were nominally lower in dapagliflozin-treated vs placebo-treated patients with biomarker concentrations in the top quartile (NT-proBNP: HR, 0.83; 95% CI, 0.71-0.97; absolute risk reduction [ARR], 2.4%; hsTnT: HR, 0.85; 95% CI, 0.72-0.99; ARR, 2.7%), whereas there was no significant treatment effect in patients with biomarkers levels in quartiles 1 to 3 (NT-proBNP: HR, 1.02; 95% CI, 0.88-1.18; ARR, 0%; hsTnT: HR, 0.97; 95% CI, 0.84-1.13; ARR, 0.2%).Conclusions and RelevanceIn this study, NT-proBNP and hsTnT levels were associated with the risk for future cardiovascular events in both primary and secondary prevention patients with T2D. Both cardiac biomarkers were helpful to identify patients at very high risk for atherosclerotic events that may derive reduction in risk of MACE with dapagliflozin.Trial RegistrationClinicalTrials.gov Identifier: NCT01730534

Published
2023
Full Text
View/download PDF

161. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update

Author

Tobe, Sheldon W., Stone, James A., Anderson, Todd, Bacon, Simon, Cheng, Alice Y.Y., Daskalopoulou, Stella S., Ezekowitz, Justin A., Gregoire, Jean C., Gubitz, Gord, Jain, Rahul, Keshavjee, Karim, Lindsay, Patty, L'Abbe, Mary, Lau, David C.W., Leiter, Lawrence A., O'Meara, Eileen, Pearson, Glen J., Rabi, Doreen M., Sherifali, Diana, Selby, Peter, Tu, Jack V., Wharton, Sean, Walker, Kimberly M., Hua-Stewart, Diane, and Liu, Peter P.

Subjects
Merck & Company Inc. -- Management, Bayer AG -- Management, Eli Lilly and Co. -- Management, Sanofi S.A. -- Management, Canadians, Evidence-based medicine, Hypertension, Type 2 diabetes, Diabetes therapy, Pharmaceutical industry, Blood glucose, Company business management, Health, Canadian Cardiovascular Society -- Management, University of Toronto -- Management
Abstract

The Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) is a nationally endorsed guideline process, targeting primary care health care practitioners. The C-CHANGE guideline is a composite of nine of Canada's [...]

Published
2018
Full Text
View/download PDF

162. Effect of Important Food Sources of Fructose-Containing Sugars on Inflammatory Biomarkers: A Systematic Review and Meta-Analysis of Controlled Feeding Trials

Author

Qi, XinYe, primary, Chiavaroli, Laura, additional, Lee, Danielle, additional, Ayoub-Charette, Sabrina, additional, Khan, Tauseef A., additional, Au-Yeung, Fei, additional, Ahmed, Amna, additional, Cheung, Annette, additional, Liu, Qi, additional, Blanco Mejia, Sonia, additional, Choo, Vivian L., additional, de Souza, Russell J., additional, Wolever, Thomas M. S., additional, Leiter, Lawrence A., additional, Kendall, Cyril W. C., additional, Jenkins, David J. A., additional, and Sievenpiper, John L., additional

Published
2022
Full Text
View/download PDF

163. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial

Author

Branch, Kelley R.H., primary, Dagenais, Gilles R., additional, Avezum, Alvaro, additional, Basile, Jan, additional, Conget, Ignacio, additional, Cushman, William C., additional, Jansky, Petr, additional, Lakshmanan, Mark, additional, Lanas, Fernando, additional, Leiter, Lawrence A., additional, Pais, Prem, additional, Pogosova, Nana, additional, Raubenheimer, Peter J., additional, Ryden, Lars, additional, Shaw, Jonathan E., additional, Sheu, Wayne H.H., additional, Temelkova‐Kurktschiev, Theodora, additional, Bethel, M. Angelyn, additional, Gerstein, Hertzel C., additional, Chinthanie, Ramasundarahettige, additional, and Probstfield, Jeffrey L., additional

Published
2022
Full Text
View/download PDF

165. Effect of oats and oat ß-glucan on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials

Author

Chen, Victoria, primary, Zurbau, Andreea, additional, Ahmed, Amna, additional, Khan, Tauseef A, additional, Au-Yeung, Fei, additional, Chiavaroli, Laura, additional, Blanco Mejia, Sonia, additional, Leiter, Lawrence A, additional, Jenkins, David J A, additional, Kendall, Cyril W C, additional, and Sievenpiper, John L, additional

Published
2022
Full Text
View/download PDF

166. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes

Author

Oyama, Kazuma, primary, Raz, Itamar, additional, Cahn, Avivit, additional, Goodrich, Erica L., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P. H., additional, Gause-Nilsson, Ingrid A. M., additional, Mosenzon, Ofri, additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2022
Full Text
View/download PDF

167. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial

Author

Mosenzon, Ofri, primary, Raz, Itamar, primary, Wiviott, Stephen D., primary, Schechter, Meir, primary, Goodrich, Erica L., primary, Yanuv, Ilan, primary, Rozenberg, Aliza, primary, Murphy, Sabina A., primary, Zelniker, Thomas A., primary, Langkilde, Anna Maria, primary, Gause-Nilsson, Ingrid A.M., primary, Fredriksson, Martin, primary, Johansson, Peter A., primary, Wilding, John P.H., primary, McGuire, Darren K., primary, Bhatt, Deepak L., primary, Leiter, Lawrence A., primary, Cahn, Avivit, primary, Dwyer, Jamie P., primary, Heerspink, Hiddo J.L., primary, and Sabatine, Marc S., primary

Published
2022
Full Text
View/download PDF

172. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Author

Gerstein, Hertzel C., Colhoun, Helen M., Dagenais, Gilles R., Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riddle, Matthew C., Rydén, Lars, Xavier, Denis, Atisso, Charles M., Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C., Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Cardona‐Munoz, Ernesto G., Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J., Shaw, Jonathan, Sheu, Wayne H‐H., and Temelkova‐Kurktschiev, Theodora

Published
2018
Full Text
View/download PDF

174. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents

Author

Davies, Melanie J., Leiter, Lawrence A., Guerci, Bruno, Grunberger, George, Ampudia‐Blasco, F. Javier, Yu, Christine, Stager, William, Niemoeller, Elisabeth, Souhami, Elisabeth, and Rosenstock, Julio

Published
2017
Full Text
View/download PDF

180. Relation of total sugars, fructose and sucrose with incident type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies

Author

Tsilas, Christine S., de Souza, Russell J., Mejia, Sonia Blanco, Mirrahimi, Arash, Cozma, Adrian I., Jayalath, Viranda H., Ha, Vanessa, Tawfik, Reem, Buono, Marco Di, Jenkins, Alexandra L., Leiter, Lawrence A., Wolever, Thomas M.S., Beyene, Joseph, Khan, Tauseef, Kendall, Cyril W.C., Jenkins, David J.A., and Sievenpiper, John L.

Subjects
Canada. Canadian Institutes of Health Research -- Analysis, Coca-Cola Co. (Atlanta, Georgia), Fructose -- Analysis, Type 2 diabetes -- Analysis, Soft drink industry -- Analysis, Beverages -- Analysis, Health, Canadian Diabetes Association
Abstract

BACKGROUND: Sugar-sweetened beverages are associated with type 2 diabetes. To assess whether this association holds for the fructose-containing sugars they contain, we conducted a systematic review and meta-analysis of prospective cohort studies. METHODS: We searched MEDLINE, Embase, CINAHL and the Cochrane Library (through June 2016). We included prospective cohort studies that assessed the relation of fructose-containing sugars with incident type 2 diabetes. Two independent reviewers extracted relevant data and assessed risk of bias. We pooled risk ratios (RRs) using random effects meta-analyses. The overall quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. RESULTS: Fifteen prospective cohort studies (251261 unique participants, 16416 cases) met the eligibility criteria, comparing the highest intake (median 137, 35.2 and 78 g/d) with the lowest intake (median 65, 9.7 and 25.8 g/d) of total sugars, fructose and sucrose, respectively. Although there was no association of total sugars (RR 0.91, 95% confidence interval [CI] 0.76-1.09) or fructose (RR 1.04, 95% CI 0.84-1.29) with type 2 diabetes, sucrose was associated with a decreased risk of type 2 diabetes (RR 0.89, 95% CI 0.80-0.98). Our confidence in the estimates was limited by evidence of serious inconsistency between studies for total sugars and fructose, and serious imprecision in the pooled estimates for all 3 sugar categories. INTERPRETATION: Current evidence does not allow us to conclude that fructose-containing sugars independent of food form are associated with increased risk of type 2 diabetes. Further research is likely to affect our estimates. Trial registration: ClinicalTrials.gov, no. NCT01608620, Sugars, particularly fructose-containing sugars, have been implicated as an important driver in the rise in incidence of type 2 diabetes. (1,2) Sugar-sweetened beverages, which represent the greatest source of fructose-containing [...]

Published
2017
Full Text
View/download PDF

181. Relation of change or substitution of low-and no-calorie sweetened beverages with cardiometabolic outcomes: A systematic review and meta-analysis of prospective cohort studies

Author

Lee, Jennifer J., primary, Khan, Tauseef A., primary, McGlynn, Nema, primary, Malik, Vasanti S., primary, Hill, James O., primary, Leiter, Lawrence A., primary, Jeppesen, Per Bendix, primary, Rahelić, Dario, primary, Kahleová, Hana, primary, Salas-Salvadó, Jordi, primary, Kendall, Cyril W. C., primary, and Sievenpiper, John L., primary

Published
2022
Full Text
View/download PDF

183. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials

Author

Lee, Danielle, primary, Chiavaroli, Laura, additional, Ayoub-Charette, Sabrina, additional, Khan, Tauseef A., additional, Zurbau, Andreea, additional, Au-Yeung, Fei, additional, Cheung, Annette, additional, Liu, Qi, additional, Qi, Xinye, additional, Ahmed, Amna, additional, Choo, Vivian L., additional, Blanco Mejia, Sonia, additional, Malik, Vasanti S., additional, El-Sohemy, Ahmed, additional, de Souza, Russell J., additional, Wolever, Thomas M. S., additional, Leiter, Lawrence A., additional, Kendall, Cyril W. C., additional, Jenkins, David J. A., additional, and Sievenpiper, John L., additional

Published
2022
Full Text
View/download PDF

184. †Efficacy and Safety of Inclisiran in Patients with Established Cerebrovascular Disease: Pooled Post hoc Analysis of the Phase 3 ORION-9, ORION-10, and ORION-11 Randomized Controlled Trials

Author

Ray, Kausik, primary, Kallend, David, additional, Landmesser, Ulf, additional, Leiter, Lawrence, additional, Schwartz, Gregory, additional, Conde, Lorena Garcia, additional, Jaros, Mark, additional, Raal, Frederick, additional, Wright, R Scott, additional, and Koenig, Wolfgang, additional

Published
2022
Full Text
View/download PDF

185. †Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled Post hoc Analysis of the phase 3 ORION-9, ORION-10, and ORION-11 Randomized Controlled Trials

Author

Ray, Kausik, primary, Kallend, David, additional, Landmesser, Ulf, additional, Leiter, Lawrence, additional, Schwartz, Gregory, additional, Conde, Lorena Garcia, additional, Wright, R Scott, additional, Jaros, Mark, additional, Raal, Frederick, additional, and Koenig, Wolfgang, additional

Published
2022
Full Text
View/download PDF

187. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial

Author

Furtado, Remo H.M., primary, Raz, Itamar, additional, Goodrich, Erica L., additional, Murphy, Sabina A., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John P.H., additional, Aylward, Philip, additional, Dalby, Anthony J, additional, Dellborg, Mikael, additional, Dimulescu, Doina, additional, Nicolau, José C., additional, Oude Ophuis, Anthonius J.M., additional, Cahn, Avivit, additional, Mosenzon, Ofri, additional, Gause-Nilsson, Ingrid, additional, Langkilde, Anna Maria, additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2022
Full Text
View/download PDF

188. Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines täglichen vs. wöchentlichen Titrationsalgorithmus für den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada

Author

Hramiak, Irene, additional, Gerstein, Hertzel C., additional, Siegmund, Thorsten, additional, Leiter, Lawrence A., additional, Yale, Jean-François, additional, Bajaj, Harpreet, additional, Stewart, John, additional, Toutounji, Marie-Josée, additional, and Harris, Stewart B., additional

Published
2022
Full Text
View/download PDF

191. Type 2 Diabetes Mellitus Management in Canada: Is It Improving?

Author

Leiter, Lawrence A., Berard, Lori, Bowering, C. Keith, Cheng, Alice Y., Dawson, Keith G., Ekoé, Jean-Marie, Fournier, Carl, Goldin, Lianne, Harris, Stewart B., Lin, Peter, Ransom, Thomas, Tan, Mary, Teoh, Hwee, Tsuyuki, Ross T., Whitham, Dana, Woo, Vincent, Yale, Jean-François, and Langer, Anatoly

Published
2013
Full Text
View/download PDF

193. Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease : a European economic evaluation of the THEMIS trial.

Author

Steg, Philippe Gabriel, Bhatt, Deepak L, James, Stefan, Darlington, Oliver, Hoskin, Louise, Simon, Tabassome, Fox, Kim M, Leiter, Lawrence A, Mehta, Shamir R, Harrington, Robert A, Himmelmann, Anders, Ridderstråle, Wilhelm, Andersson, Marielle, Bueno, Héctor, De Luca, Leonardo, Tank, Amarjeet, Mellström, Carl, McEwan, Phil, Steg, Philippe Gabriel, Bhatt, Deepak L, James, Stefan, Darlington, Oliver, Hoskin, Louise, Simon, Tabassome, Fox, Kim M, Leiter, Lawrence A, Mehta, Shamir R, Harrington, Robert A, Himmelmann, Anders, Ridderstråle, Wilhelm, Andersson, Marielle, Bueno, Héctor, De Luca, Leonardo, Tank, Amarjeet, Mellström, Carl, and McEwan, Phil

Abstract

AIMS: To conduct a health economic evaluation of ticagrelor in patients with type 2 diabetes and coronary artery disease (CAD) from a multinational payer perspective. Cost-effectiveness and cost-utility of ticagrelor were evaluated in the overall effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) trial population and in the predefined patient group with prior percutaneous coronary intervention. METHODS AND RESULTS: A Markov model was developed to extrapolate patient outcomes over a lifetime horizon. The primary outcome was incremental cost-effectiveness ratios (ICERs), which were compared with conventional willingness-to-pay thresholds [€47 000/quality-adjusted life-year (QALY) in Sweden and €30 000/QALY in other countries].Treatment with ticagrelor resulted in QALY gains of up to 0.045 in the overall population and 0.099 in patients with percutaneous coronary intervention (PCI). Increased costs and benefits translated to ICERs ranged between €27 894 and €42 252/QALY across Sweden, Germany, Italy, and Spain in the overall population. In patients with prior PCI, estimated ICERs improved to €18 449, €20 632, €20 233, and €13 228/QALY in Sweden, Germany, Italy, and Spain, respectively, driven by higher event rates and treatment benefit. CONCLUSION: Based on THEMIS results, ticagrelor plus aspirin compared with aspirin alone may be cost-effective in some European countries in patients with T2DM and CAD and no prior myocardial infarction (MI) or stroke. Additionally, ticagrelor is likely to be cost-effective across European countries in patients with a history of PCI.

Published
2022
Full Text
View/download PDF

194. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes:Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

Author

Strain, W. David, Frenkel, Ofir, James, Martin A., Leiter, Lawrence A., Rasmussen, Søren, Rothwell, Peter M., Sejersten Ripa, Maria, Truelsen, Thomas C., Husain, Mansoor, Strain, W. David, Frenkel, Ofir, James, Martin A., Leiter, Lawrence A., Rasmussen, Søren, Rothwell, Peter M., Sejersten Ripa, Maria, Truelsen, Thomas C., and Husain, Mansoor

Abstract

Background: GLP-1 RA (glucagon-like peptide-1 receptor agonists), including semaglutide, may reduce stroke risk in people with type 2 diabetes. This post hoc analysis examined the subcutaneous and oral semaglutide effects, versus placebo, on stroke and its subtypes in people with type 2 diabetes at high cardiovascular risk. Methods: SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) and PIONEER 6 (Peptide Innovation for Early Diabetes Treatment) were randomized cardiovascular outcome trials of subcutaneous and oral semaglutide in people with type 2 diabetes at high cardiovascular risk, respectively. Time to first stroke and stroke subtypes were analyzed using a Cox proportional hazards model stratified by trial with pooled treatment as a factor. The impact of prior stroke, prior myocardial infarction or stroke, age, sex, systolic blood pressure, estimated glomerular filtration rate, and prior atrial fibrillation on treatment effects was assessed using interaction P values. Risk of major adverse cardiovascular event was analyzed according to prior stroke. Results: A total of 106/6480 participants had a stroke (1.0 event/100 patient-years of observation [PYO]). Semaglutide reduced incidence of any stroke versus placebo (0.8 versus 1.1 events/100 PYO; hazard ratio, 0.68 [95% CI, 0.46-1.00]; P=0.048), driven by significant reductions in risk of small-vessel occlusion (0.3 versus 0.7 events/100 PYO; hazard ratio, 0.51 [95% CI, 0.29-0.89]; P=0.017). Hazard ratios for risk of any stroke with semaglutide versus placebo were 0.60 (95% CI, 0.37-0.99; 0.5 versus 0.9 events/100 PYO) and 0.89 (95% CI, 0.47-1.69; 2.7 versus 3.0 events/100 PYO) in those without and with prior stroke, respectively. Except for prior atrial fibrillation (Pinteraction=0.025), no significant interactions were observed between treatment effects on risk of any stroke and subgroups investigated, or between treatment eff

Published
2022

195. Teleconferenced Educational Detailing: Diabetes Education for Primary Care Physicians

Author

Harris, Stewart B., Leiter, Lawrence A., and Webster-Bogaert, Susan

Abstract

Introduction: Formal didactic continuing medical education (CME) is relatively ineffective for changing physician behavior. Diabetes mellitus is an increasingly prevalent disease, and interventions to improve adherence to clinical practice guidelines (CPGs) are needed. Methods: A stratified, cluster-randomized, controlled trial design was used to evaluate the effects of a teleconferenced educational detailing (TED) CME on glycemic control (hemoglobin [Hb] A[subscript 1c]) and family physician adherence to national diabetes guidelines. TED employed sequential, small-group, case-based education using CPGs delivered by a diabetes specialist. Medical record audit data from baseline through the end of a 12-month postintervention period were compared for the control and intervention groups. Satisfaction with the intervention was evaluated. Results: Sixty-one physicians provided 660 medical records. The intervention did not affect mean Hb A[subscript 1c] levels but did significantly (p = 0.04) alter the distribution of patients by category of glycemic control, with fewer in the intervention group in inadequate control (15.8% versus 23.9%). More patients took insulin (alone or with oral agents) in the intervention group (21.2% versus 12.0%, p = 0.03), and more took oral agents only in the control group (89.0% versus 82.9%, p = 0.005). More patients in the intervention group had documentation of body mass index (7.8% versus 1.9%, p less than 0.02), eye exam (12.1% versus 5.1%, p = 0.02), and treatment plan (43.5% versus 23.6%, p = 0.01) and used a flow sheet (14.6% versus 7.7%, p less than 0.03). Although there was general satisfaction with the teleconferencing format, specialist educators found the format more challenging than the family physicians. Discussion: CME delivered by teleconference was feasible, well attended, well received by participants, and improved some key diabetes management practices and outcomes.

Published
2005
Full Text
View/download PDF

198. Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial

Author

Steg, Philippe Gabriel, primary, Bhatt, Deepak L, additional, James, Stefan K, additional, Darlington, Oliver, additional, Hoskin, Louise, additional, Simon, Tabassome, additional, Fox, Kim M, additional, Leiter, Lawrence A, additional, Mehta, Shamir R, additional, Harrington, Robert A, additional, Himmelmann, Anders, additional, Ridderstråle, Wilhelm, additional, Andersson, Marielle, additional, Bueno, Héctor, additional, De Luca, Leonardo, additional, Tank, Amarjeet, additional, Mellström, Carl, additional, and McEwan, Phil, additional

Published
2022
Full Text
View/download PDF

199. Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial

Author

Cukierman-Yaffe, Tali, primary, Gerstein, Hertzel C, additional, Basile, Jan, additional, Bethel, M Angelyn, additional, Cardona-Muñoz, Ernesto G, additional, Conget, Ignacio, additional, Dagenais, Gilles, additional, Franek, Edward, additional, Hall, Stephanie, additional, Hancu, Nicolae, additional, Jansky, Petr, additional, Lakshmanan, Mark, additional, Lanas, Fernando, additional, Leiter, Lawrence A, additional, Lopez-Jaramillo, Patricio, additional, Pirags, Valdis, additional, Pogosova, Nana, additional, Probstfield, Jeffrey, additional, Rao-Melacini, Purnima, additional, Ramasundarahettige, Chinthanie, additional, Raubenheimer, Peter J, additional, Riddle, Matthew C, additional, Rydén, Lars, additional, Shaw, Jonathan E, additional, Sheu, Wayne H-H, additional, and Temelkova-Kurktschiev, Theodora, additional

Published
2022
Full Text
View/download PDF

200. A Web-Based Health Application to Translate Nutrition Therapy for Cardiovascular Risk Reduction in Primary Care (PortfolioDiet.app): Quality Improvement and Usability Testing Study

Author

Kavanagh, Meaghan E, primary, Chiavaroli, Laura, additional, Glenn, Andrea J, additional, Heijmans, Genevieve, additional, Grant, Shannan M, additional, Chow, Chi-Ming, additional, Josse, Robert G, additional, Malik, Vasanti S, additional, Watson, William, additional, Lofters, Aisha, additional, Holmes, Candice, additional, Rackal, Julia, additional, Srichaikul, Kristie, additional, Sherifali, Diana, additional, Snelgrove-Clarke, Erna, additional, Udell, Jacob A, additional, Juni, Peter, additional, Booth, Gillian L, additional, Farkouh, Michael E, additional, Leiter, Lawrence A, additional, Kendall, Cyril WC, additional, Jenkins, David JA, additional, and Sievenpiper, John L, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results